medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 6

<< Back Next >>

Rev Invest Clin 2011; 63 (6)

The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients

Rosas-Carrasco Ó, García-Peña C, Sánchez-García S, Vargas-Alarcón G, Gutiérrez-Robledo LM, Juárez-Cedillo T

Language: English
References: 35
Page: 564-573
PDF size: 152.64 Kb.


ABSTRACT

Background. The increase in drug-drug interactions (potential DDIs) is a consequence that older adults experience by high availability of prescription medications for an increasing variety of diseases. This increase in potential DDIs could be associated with mortality rate during hospitalization. Objective. To determine whether the association between the presence of Potential DDIs and mortality rate in hospitalized elderly and to describe the frequency of potential DDIs and characterize drugs. Material and methods. A retrospective research was performed by reviewing the medical records of patients 60 years and older who were admitted to a second-level care hospital. The Potential DDIs were identified through the Micromedex® program. Comorbidity was classified according to the Charlson Index (CCI). Other variables such as gender, age, number and type of drug, type of interaction, and duration of hospital stay were evaluated. Results. 505 patients were included, among whom the 62.77% presented at least one type of DDI. We found that 15.25% of moderate interactions were due to the combined use of angiotensin converting enzyme inhibitors and loop diuretics. Among serious interactions, 14.92% occurred due to the combined use of fluroquinolones and hypoglycemic agents. The duration of stay and a high comorbidity score, the presence of three or more interactions and exposure time to the interaction, were independently associated with mortality rate. Conclusions. This work shows that the occurrence of potential DDIs in the hospital environment for the elderly population is frequent and may be implicated in the cause of death for these patients.


REFERENCES

  1. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13: 306-14.

  2. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Therap 2008; 33: 141-51.

  3. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000; 50: 172-5.

  4. Doubova SV, Torres-Arreola LP, Rosas-Carrasco O, Pérez- Cuevas R. Quality of medication prescribing for elderly patients with non-malignant pain syndrome attending family medicine clinics. Rev Invest Clin 2007; 59: 428-36.

  5. Radosevic N, Gantumur M, Vlahovic-Palcevski V. Potentially inappropriate prescribing to hospitalized patients. Pharmacoepidemiol Drug Saf 2008; 17: 733-7.

  6. Peral AJ, Lertxundi EU, Martínez BMJ Prospective assessment of drug interactions in hospitalized patients using a computer programme. Farm Hosp 2007; 31: 93-100.

  7. Lima RE, De Bortoli CSH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem 2009; 17: 222-7.

  8. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-50.

  9. Nixdorff N, Hustey FM, Brady AK, Vaji K, Leonard M, Messinger- Rapport BJ. Potentially inappropriate medications and adverse drug effects in elders in the ED. Am J Emerg Med 2008; 26: 697-70.

  10. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalizations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007; 16: 641-51.

  11. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalization and mortality: a population-based study of the very old. Drugs Aging 2005; 22: 69-82.

  12. Hanlon JT, Fillenbaum GG, Kuchibhatla M, Artz MB, Boult C, Gross CR, et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care 2002; 40: 166-76.

  13. Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci 2006; 61: 170-5.

  14. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a Department of Internal Medicine. Arch Intern Med 2001; 161: 2317-23.

  15. Implementation of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD- 10). Epidemiol Bull 1997; 18: 1-4.

  16. WHO. Collaborating Centre for Drug Statistics Methodology: About the ATC/DDD system. Available from: http://www.whocc.no/atcddd/ [Accessed 18 September 2009].

  17. Micromedex and Drogas- Reax. Available from: http:// www.micromedex.com [Accessed 18 September 2009].

  18. Charlson M, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.

  19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-9; discussion 1081-90.

  20. SPSS. SPSS for Windows, Version 13. Chicago, IL: SPSS, 2001.

  21. Peral J, Lertxundi EU, Martínez BMJ. Prospective assessment of drug interactions in hospitalized patients using a computer programme. Farm Hosp 2007; 31: 93-100.

  22. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-20.

  23. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8.

  24. Davies MK, Gibbs CR, Lip GY. ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates. BMJ 2000; 320: 428-31.

  25. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004; 24: 1807-12.

  26. Garber SM, Pound MW, Miller SM. Hypoglycemia associated with the use of levofloxacin. Am J Health Syst Pharm 2009; 66: 1014-19.

  27. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). Am J Cardiol 1997; 79: 115-19.

  28. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920-5.

  29. Peterson JG, Laur MS, Young JB, et al. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-I Trial. J Am Coll Cardiol 1998 (Suppl. A): 96A.

  30. EMPS. Agencia española de medicamentos y productos sanitarios. Disponible en: http://www.aemps.es/actividad/notaMensual/ 2010/mayo2010/nota_medicamentos.htm [Accesed 9 January 2010].

  31. Cruciol-Souza JM, Thomson JC. Prevalence of potential drugdrug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006; 9: 427-33.

  32. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci 2009; 12: 266-72.

  33. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalization and mortality: a population- based study of the very old. Drugs Aging 2005; 22: 69-82.

  34. Terleira A, Portoles A, Rojas A, Vargas E. Effect of drug-test interactions on length of hospital stay. Pharmacoepidemiol Drug Saf 2007; 16: 39-45.

  35. Farmacovigilancia Instituto Mexicano del Seguro Social (IMSS). Disponible en: http://www imss.gob.mx/transparencia/ cuadros/farmacovigilancia/organizacion [Accessed: 26 October 2009].




2020     |     www.medigraphic.com